172 related articles for article (PubMed ID: 22829507)
1. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.
Gil RJ; Vassilev D; Michalek A; Kern A; Formuszewicz R; Dobrzycki S; Wójcik J; Lesiak M; Kardaszewicz P; Lekston A
EuroIntervention; 2012 Jul; 8(3):316-24. PubMed ID: 22829507
[TBL] [Abstract][Full Text] [Related]
2. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
[TBL] [Abstract][Full Text] [Related]
3. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
[TBL] [Abstract][Full Text] [Related]
4. First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent.
Ormiston JA; Lefèvre T; Grube E; Allocco DJ; Dawkins KD
EuroIntervention; 2010 May; 6(1):46-53. PubMed ID: 20542797
[TBL] [Abstract][Full Text] [Related]
5. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.
Bil J; Gil RJ; Vassilev D; Rzezak J; Kulawik T; Pawlowski T
J Interv Cardiol; 2014 Jun; 27(3):242-51. PubMed ID: 24708143
[TBL] [Abstract][Full Text] [Related]
6. Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Ferenc M; Silber S; Sabin G; Tebbe U; Akin I; Hochadel M; Senges J; Kuck KH; Richardt G;
J Interv Cardiol; 2012 Aug; 25(4):344-52. PubMed ID: 22409587
[TBL] [Abstract][Full Text] [Related]
7. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
Gil RJ; Bil J; Kern A; Pawłowski T
Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
9. 3-year follow-up of 100 consecutive coronary bifurcation lesions treated with Taxus stents and the crush technique.
Chue CD; Routledge HC; Ludman PF; Townend JN; Epstein AC; Buller NP; Doshi SN
Catheter Cardiovasc Interv; 2010 Mar; 75(4):605-13. PubMed ID: 20066725
[TBL] [Abstract][Full Text] [Related]
10. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
[TBL] [Abstract][Full Text] [Related]
11. The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions.
Lefèvre T; Ormiston J; Guagliumi G; Schultheiss HP; Quilliet L; Reimers B; Brunel P; Wijns W; Buettner HJ; Hartmann F; Veldhof S; Miquel K; Su X; van der Giessen WJ
J Am Coll Cardiol; 2005 Aug; 46(4):592-8. PubMed ID: 16098421
[TBL] [Abstract][Full Text] [Related]
12. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
[TBL] [Abstract][Full Text] [Related]
14. A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry.
Agostoni P; Foley D; Lesiak M; Belkacemi A; Dens J; Kumsars I; Scott B; Oemrawsingh P; Dubois C; Garcia E; Lefèvre T; Stella PR
EuroIntervention; 2012 Mar; 7(11):1293-300. PubMed ID: 22433192
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of a dedicated bifurcation stent system.
Sivalingam J; Mazhar MW; Chaddad RA; Fouladvand F; Cortese B
Cardiovasc Revasc Med; 2024 Feb; 59():21-26. PubMed ID: 37666716
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of bifurcation lesions after implantation of drug-eluting stents with the "mini-crush technique".
Galassi AR; Colombo A; Buchbinder M; Grasso C; Tomasello SD; Ussia GP; Tamburino C
Catheter Cardiovasc Interv; 2007 Jun; 69(7):976-83. PubMed ID: 17295334
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
18. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
19. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study.
Biondi-Zoccai GG; Sangiorgi GM; Antoniucci D; Grube E; Di Mario C; Reimers B; Tamburino C; Agostoni P; Cosgrave J; Colombo A;
Int J Cardiol; 2007 May; 117(3):349-54. PubMed ID: 16859781
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
